BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
445 results:

  • 1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
    Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
    J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Activation of the pi3k/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
    Ge W; Wang Y; Quan M; Mao T; Bischof EY; Xu H; Zhang X; Li S; Yue M; Ma J; Yang H; Wang L; Yu Z; Wang L; Cui J
    Mol Cancer; 2024 Mar; 23(1):48. PubMed ID: 38459558
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
    Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
    J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro.
    Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
    Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated pi3k/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms.
    Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
    J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. NUDT21 interacts with NDUFS2 to activate the pi3k/AKT pathway and promotes pancreatic cancer pathogenesis.
    Huang XD; Chen YW; Tian L; Du L; Cheng XC; Lu YX; Lin DD; Xiao FJ
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):8. PubMed ID: 38195952
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.
    Ma Z; Gu Q; Dai Y; Wang Q; Shi W; Jiao Z
    Cancer Sci; 2024 Mar; 115(3):820-835. PubMed ID: 38151993
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
    Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
    Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
    Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
    Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Neuromedin U regulates the anti-tumor activity of CD8
    Zheng R; Wang S; Wang J; Zhou M; Shi Q; Liu B
    Cancer Sci; 2024 Feb; 115(2):334-346. PubMed ID: 38071753
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
    Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
    Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy.
    Montenegro MF; Martí-Díaz R; Navarro A; Tolivia J; Sánchez-Del-Campo L; Cabezas-Herrera J; Rodríguez-López JN
    Cell Death Dis; 2023 Nov; 14(11):761. PubMed ID: 37996408
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. USP11 potentiates HGF/AKT signaling and drives metastasis in hepatocellular carcinoma.
    Chen J; Ning D; Du P; Liu Q; Mo J; Liang H; Zhang W; Zhang M; Jiang L; Zhang B; Chen X
    Oncogene; 2024 Jan; 43(2):123-135. PubMed ID: 37973952
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. AUM302, a novel triple kinase PIM/pi3k/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
    Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
    PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Impact of the pi3k-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model.
    Mohan AM; Prasad S; Schmitz-Peiffer F; Lange C; Lukas M; Koziolek EJ; Albrecht J; Messroghli D; Stein U; Ilmer M; Wang K; Schober L; Reul A; Maurer J; Friemel J; Weber A; Zuellig RA; Hantel C; Fritsch R; Reincke M; Pacak K; Grossman AB; Auernhammer CJ; Beuschlein F; Brenner W; Beindorff N; Nölting S
    Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 37943630
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
    Sohel M
    Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 23.